Last C$0.17 CAD
Change Today 0.00 / 0.00%
Volume 3.3M
SBM On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 3:57 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

sirona biochem corp (SBM) Snapshot

Open
C$0.18
Previous Close
C$0.17
Day High
C$0.19
Day Low
C$0.16
52 Week High
08/6/14 - C$0.20
52 Week Low
07/18/14 - C$0.09
Market Cap
22.1M
Average Volume 10 Days
1.2M
EPS TTM
C$-0.03
Shares Outstanding
130.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SIRONA BIOCHEM CORP (SBM)

Related News

No related news articles were found.

sirona biochem corp (SBM) Related Businessweek News

No Related Businessweek News Found

sirona biochem corp (SBM) Details

Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada. The company develops programs in three areas, including diabetes and cancer therapeutics; anti-aging and depigmenting agent in cosmeceuticals; biological ingredients, such as inducers and adjuvants for biological development. It develops a sodium glucose co-transporter inhibitor for the treatment of Type 2 diabetes; and a cancer vaccine antigen. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Founded in 2006

sirona biochem corp (SBM) Top Compensated Officers

Founder, Chairman of the Board, Interim Chief...
Total Annual Compensation: C$95.0K
Chief Financial Officer and Director
Total Annual Compensation: C$102.0K
Compensation as of Fiscal Year 2013.

sirona biochem corp (SBM) Key Developments

Sirona Biochem Appoints Martin Gleave to its Board of Directors

Sirona Biochem Corp. announced the appointment of Dr. Martin Gleave to its Board of Directors. Dr. Gleave holds numerous leadership positions in research and academia. He is currently distinguished Professor and Vice Chair of the Department of Urologic Sciences at UBC, and Director at the Vancouver Prostate Centre (VPC).

Sirona Reports Earnings Results for the Fourth Quarter of 2014

Sirona reported earnings results for the fourth quarter of 2014. For the quarter, the company reported total revenue of $290.0 million, increasing 4% compared to $278.6 million in the fourth quarter of 2013. Gross margin increased to 55.1% from 51.4% in the fourth quarter of 2013.

Sirona Biochem Names Attila Hajdu as Chief Business Development Officer

Sirona Biochem Corp. announced that it has named Mr. Attila Hajdu as Chief Business Development Officer. Prior to joining Sirona Biochem, Attila held various senior leadership positions within GlaxoSmithKline and Astellas Pharma, accumulating 17 years of experience in Sales, Marketing, R&D Finance, Medical Affairs and Business Development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SBM:CN C$0.17 CAD 0.00

SBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SBM.
View Industry Companies
 

Industry Analysis

SBM

Industry Average

Valuation SBM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 69.1x
Price/Book 11.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 70.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIRONA BIOCHEM CORP, please visit www.sironabiochem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.